Prof. Dr. Volker Ellenrieder

Further involvements

• Th, 15/02

  14:40 – 14:50 8 Min. 2 Min.

  • Oral presentation
  • O07

  Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response via AP1 dichotomy in pancreatic cancer

   Tumour microenvironment, epigenetics and stem cells
• Th, 15/02

  16:20 – 16:25 3 Min. 2 Min.

  • ePoster presentation
  • P16

  The oral microbiome is associated with preoperative imaging criteria and histological alterations in IPMN patients – a pilot study

   Cystic lesions of the pancreas
• Th, 15/02

  16:35 – 16:40 3 Min. 2 Min.

  • ePoster presentation
  • P08

  Mechanisms of CRAC-NFATc1 signaling in acute pancreatitis

   Acute/chronic pancreatitis
• Th, 15/02

  16:40 – 16:45 3 Min. 2 Min.

  • ePoster presentation
  • P09

  Pancreaticobiliary tumors reveal a distinct and entity-specific orointestinal microbiome

   Pancreatic cancer
• Th, 15/02

  17:10 – 17:20 8 Min. 2 Min.

  • Oral presentation
  • O10

  Crosstalk of glutamine metabolism and NFATc1 – unfolding vulnerabilities for enhanced therapeutic efficacy in PDAC

   Pancreatic cancer
• Fr, 16/02

  09:10 – 09:20 8 Min. 2 Min.

  • Oral presentation
  • O22

  Pancreatic fistula can be predicted by the oral microbiome and body mass index

   Pancreatic surgery / Robotics
• Fr, 16/02

  14:45 – 14:50 3 Min. 2 Min.

  • ePoster presentation
  • P29

  Distinct TP53 missense mutations induce diverging pathways to foster pancreatic cancer aggressiveness

   Pancreatic cancer
• Fr, 16/02

  17:15 – 17:25 8 Min. 2 Min.

  • Oral presentation
  • O35

  Gut microbiota predicts severity, mortality, length of hospital stay and reveals novel metabolic pathways in severe acute pancreatitis

   Acute/chronic pancreatitis
• Sa, 17/02

  09:50 – 10:00 8 Min. 2 Min.

  • Oral presentation
  • O52

  PROTOCOL trial – PROTon pump inhibitors and stent OCclusion rate Of Lumen apposing metal stents

   Acute/chronic pancreatitis
• Sa, 17/02

  10:05 – 10:10 3 Min. 2 Min.

  • ePoster presentation
  • P45

  KRASG12C inhibitor-based combination therapies for pancreatic cancer: Insights from drug screening

   Pancreatic cancer
• Sa, 17/02

  10:35 – 10:40 3 Min. 2 Min.

  • ePoster presentation
  • P62

  GSK3ß;NFATc1 Subtype-Specific targeting in pancreatic cancer

   Pancreatic cancer
• Sa, 17/02

  13:50 – 14:00 8 Min. 2 Min.

  • Oral presentation
  • O61

  Molecular characterization of the cell-intrinsic mechanisms driving NFATc1:STAT3-mediated PDAC tumor heterogeneity

   Pancreatic cancer